English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, May 25, 2018
筑波大・EAファーマ・エーザイ、炎症性腸疾患の治療に有用な新規抗炎症メカニズムを解明
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib
エーザイ、MSDとの「レンバチニブ」の切除不能な肝細胞がんに係る承認申請の米国FDAによる審査終了目標日延長について
Wednesday, May 23, 2018
エーザイとPurdue Pharma、「レンボレキサント」に関する最新の臨床第Ⅰ相試験結果を第32回米国睡眠学会年次総会において発表
Eisai and Purdue Pharma to Present Latest Phase I Clinical Data on Lemborexant at 32nd Annual Sleep Meeting
Thursday, May 17, 2018
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting
Monday, April 23, 2018
エーザイ、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」に関する権利をRiemser社に譲渡
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser
Friday, April 20, 2018
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575